ATI-2341 acetate(1337878-62-2 free base)
Code | Size | Price |
---|
TAR-T6764L-1mg | 1mg | £176.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6764L-5mg | 5mg | £432.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6764L-10mg | 10mg | £603.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6764L-25mg | 25mg | £863.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6764L-50mg | 50mg | £1,187.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6764L-100mg | 100mg | £1,581.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
ATI-2341 acetate is an effective allosteric agonist of CXCR4, it activates Gα1 instead of Gα13. ATI-2341 acetate activates inhibitory heterotrimeric G protein (GI) to promote the inhibition of cAMP production and induce calcium mobilization.
CAS:
T6764L
Formula:
C106H182N26O27S2
Molecular Weight:
2316.87
Pathway:
Autophagy; GPCR/G Protein; Immunology/Inflammation
Purity:
0.9714
SMILES:
CCCCCCCCCCCCCCCC(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC(C)C)=O)CCCNC(N)=N)=O)CC1=CC=C(C=C1)O)=O)CCCCN)=O)CC(O)=O)=O)[C@H](O)C)=O)CCSC)=O)CO)=O)CCCNC(N)=N)=O)CC(C)C)=O)CCCCN)=O)CCCCN)=O)CCC(N)=O)=O)CC2=CC=C(C=C2)O)=O)=O)CCSC)=O.CC(O)=O
Target:
CXCR
References
Tchernychev B , Ren Y , Sachdev P , et al. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells[J]. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(51):p.22255-22259.